In this study, we intended to test the hypothesis that the use of a non-residualizing radioiodine label would improve the tumor-to-liver ratio for the HER3-targeting ZHER3:08698 affibody molecule compared to a residualizing radiometal label. The gene discussed is ERBB3; the disease is neoplasm.